Download presentation
Presentation is loading. Please wait.
1
Mitigating Infection Risk With DMT in MS
2
Evolving Therapeutic Landscape in MS
3
Potential for Infectious Risk With Maintenance Therapy vs IRT
4
Selectivity of Infectious Agents According to the Nature of Immunosuppression
5
Listeria Infection With Alemtuzumab
6
Herpes Zoster Infection
7
VZV Vaccination
8
PML Surveillance in Patients Treated With Natalizumab
9
HPV Infection
10
Screening for Infections Before Starting DMTs
11
Immunoglobulin Levels and Infection Risk With Anti-CD20 mAbs
12
Vaccinating Against Encapsulated Bacteria
13
Use of Live Vaccines
14
Use of Prophylactic Anti-Infective Agents
15
Extended-Interval Dosing of Natalizumab to Reduce PML Risk
16
PLEX to Accelerate Natalizumab Clearance and Limit PML Infection
17
Rare Infections With Fingolimod
18
Infections With DMF
19
Infections With Cladribine
20
Infections With Ocrelizumab
21
Conclusions
22
Abbreviations
23
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.